Introduction
Pancreatic cancer is the 8 th leading cause of cancer death worldwide and it is the 4 th leading cause of cancer deaths in the United States (US). The incidence and death rates for pancreatic cancer are rising. It is estimated that pancreatic cancer incidence and mortality will be approximately 46,420 and 39,590 respectively in 2014 (1) . It is projected that by 2030, pancreatic cancer will likely be the 2 nd leading cause of cancer-related death in the USA (2) . The prognosis for pancreatic cancer is extremely poor. (3) (4) (5) . Combination cytotoxic therapies, including FOLFIRINIX and gemcitabine with nab-paclitaxel have showed clinically meaningful improvements over the single agent gemcitabine which was the prior standard of care, however the median survival benefit is an additional 4-6 months [5] [6] [7] [8] . Regardless of current therapies, less than 5% of patients with pancreatic cancer survive for 5 years due to the aggressiveness of the disease and the lack of effective therapies (3) (4) (5) . Therefore, development of new therapeutic compounds is needed.
. . Natural compounds and novel synthetic drugs have been shown to induce the process of apoptosis by altering various signaling pathways. Xanthohumol (XN), a natural flavonoid isolated from the cones of the hop plant (Humulus lupulus L.), has been shown to inhibit cancer cell proliferation in vitro in various solid organ human malignancies such as breast, colon, prostate, ovarian, hepatocellular, and medullary thyroid cancers (6) (7) (8) (9) (10) (11) (12) . XN has also been shown to reduce growth by inducing apoptosis, both caspase dependent and independent, in cancer cells (13, 14) . In vivo, oral administration of XN showed delayed advanced tumor progression and also reduced cell growth of poorly differentiated prostrate carcinoma [16] . In addition, XN exerts a broad range of biological activities such as antioxidant, anti-inflammatory, antimicrobial, immune modulatory activity, and may also have therapeutic potential for metabolic diseases including type 2 diabetes, a risk factor for the development of pancreatic cancer (15) (16) (17) (18) (19) (20) (21) . However, the biological effects of XN in pancreatic cancer are not known. In the present study, we investigated the antiproliferative effects of XN on established human pancreatic cancer cell lines and cells derived from human pancreatic cancer tissues. We found that XN inhibited cellular growth in a dose and time dependent manner. Treatment of pancreatic cancer cell lines with XN also induced apoptosis, demonstrated growth suppression which was associated with reduction in Notch pathway proteins and mRNA, and resulted in reduction in Notch1 promoter activity. Importantly, overexpression of active Notch1 negated the growth suppressive effect of XN in pancreatic cancer cell lines. These findings suggested that growth suppression of pancreatic cancer cells by XN may be mediated by Notch1 reduction.
Materials and Methods

Cell lines and culture conditions
The human pancreatic cancer cell lines (AsPC-1, PANC-1, and MiaPaCa-2) and human normal fetal lung fibroblast, WI-38, were purchased in 2012 from American Type Culture Collection (ATCC, Rockville, MD, USA) and expanded and frozen several vials after 3 rd generation. Experiments were carried out with in the 15-20 passages of each thawing of cells.
Reagents
Xanthohumol (XN) and 1-chloro-2,4-dimethylthylthiazol-2yl-2,5-dipheynltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich (St.Louis, MO, USA). The XN was solubilized in DMSO at stock concentrations of 50mM and diluted in the media when used for treatment. Antibodies against survivin, glyceraldehyde phosphate dehydrogenase (GAPDH), Notch1, HES-1, and caspase-3 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and cleaved caspase-3 and cleaved PARP were obtained from Cell Signaling Technology Inc. (Denvers, MA, USA) respectively.
Cell proliferation, viability, and colony forming ability assays
Cells were seeded in 24-well plates and were treated with different concentrations of XN for up to 96 hours. Cell proliferation/viability was measured by using colorimetric assay with MTT (22). Cell viability was also assessed by trypan blue staining. The results represent the average of three experiments each conducted in quadruplicates. Values were calculated to percent inhibition relative to vehicle control (0.1% DMSO). The effect of XN on colony forming ability was determined by the measurement of the colonogenic cell survival as previously described (22). 
Non-invasive cellular proliferation assay in real time
Western blot analysis
Western blot analyses were conducted as previously described (22).
Cells were lysed in radioimmunoprecipitation assay (RIPA, Thermo Fisher) buffer supplemented with protease inhibitor cocktail (Sigma) and phenylmethylsulfonylfluoride (Sigma). Equal amount of proteins were quantified by bicinchonic method (BCA, Thermo Fisher) and analyzed by SDS-PAGE (Bio-Rad Laboratories, Hercules, CA, USA). Then the proteins were transferred to nitrocellulose membranes (Bio-Rad) using a Trans-Blot (Bio-Rad) and analyzed by specific antibodies as indicated in the experiments. The detection of immune complexes was conducted using chemiluminescence with an HRP antibody detection kit and then images were taken using Molecular Imager TM ChemiDoc XRS + imager with image lab software (Bio-Rad).
Caspase-3 and -7 activities
Caspase-Glo 3/7 Assay (Promega, Madison, WI, USA) kit was used to measure the cleaved caspase- 
Real-time reverse transcriptase polymerase chain reaction (RT-PCR)
RT-PCR was conducted to quantify gene expression using mRNA from control or XN treated cells.
Total RNA (1µg) was reverse transcribed using either iScript cDNA Synthesis Kit (Bio-Rad) or Reverse
Transcriptase 2X Mastermix (MidSci, St. Louis, MO, USA) and PCR was carried out using Table 1 . Data were analyzed as per to the comparative C T method and normalized for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression in each sample.
Luciferase reporter assay
To determine the effect of XN on Notch1 promoter, pancreatic cancer cells were transfected with luciferase reporter gene under the control of Notch1 promoter as previously described (24 
Statistical analysis
Analysis of variance (ANOVA) with Bonferroni post hoc testing was performed using a statistical analysis software package (IBM SPSS Statistics version 22, New York, NY, USA). A P value of < 0.05 was considered significant. Data were represented as ± standard error. (Fig. 1B) . This was further confirmed by assessing the colony forming ability of these cell lines after XN treatment. As shown in Fig. 1C 
Results
Effects of Xanthohumol on pancreatic cancer cells proliferation
Xanthohumol induces apoptosis in pancreatic cancer cells
To determine if the increased antiproliferative effect of XN maybe be due to apoptosis, we analyzed (Fig 4C) . However, increased concentrations of XN caused decrease in luciferase activity in plasmid containing Notch1 promoter suggesting that XN affects the Notch1 promoter activity (Fig. 4C) which leads to the decrease in the levels of Notch1 mRNA and protein levels. Notch pathway via antibody therapy or by gamma secretase inhibitors (48, 49) . In addition to it's role in pancreatic cancer pathogenesis, Notch1 may be an important factor in the development of chemotherapeutic resistance. One cause of resistance to drug treatment in pancreatic cancer is an increase in nuclear transcription factor kB (NF-kB) promoter activity by Notch1 (50).
Xanthohumol (XN), a flavonoid compound isolated from hop plant, humulus lupulus, has significant antitumor activities against breast, prostate, ovarian, thyroid, colon, and hepatocellular cancer cells (6-8, 12, 14, 25, 51-54) . Therefore, in recent years, XN has received much attention for its biological effects. Pharmacological aspects of XN and its effects are described (55) . XN has been shown to inhibit cancer cell proliferation by association with reduction in several major targets such as NF-kB activation, drug efflux transporters expression, angiogenesis, AKT/NF-kB, and Notch1 (11, 12, 25, (56) (57) (58) (59) (60) . However, the underlying molecular mechanism by which XN inhibits growth is still not clear. It has also been shown to induce caspase dependent as well as caspase independent apoptosis, and inhibit cell invasion (8, 9, 13, 14) . We have previously shown that XN treatment in medullary thyroid cancer cells resulted in suppression of transcription factor achaete scute complex-like1 (ASCL1) with concomitant induction of phosphorylation of ERK1/2 and reduction in growth (6) . There is a single report on XN reduces Notch1 at both mRNA and protein level in ovarian cancer cells in vitro (25).
However, the findings in their report, in our opinion, lack functional analysis to confirm the role of Notch1 in XN treated cells. Though similar growth suppression effect is observed in variety of cancers, the associated effects are correlative. In the present study, we have shown that XN inhibits growth of human pancreatic cancer cell lines in vitro with a concomitant induction of apoptosis in a dosedependent manner. We observed a significant reduction in Notch1 signaling pathway members such as Notch1, HES-1, basic helix-loop-helix transcription factor, and survivin both at mRNA and protein levels when treated with XN. Importantly, down regulation of Notch1 signaling pathway appears to be the mechanism of growth suppression because over expression of Notch1 negated the growth suppression effect of XN. Therefore, we believe that our research findings are significant for Furthermore, our results indicated that XN treatment reduced Notch expression that may lead to a reduction in NF-kB activity and therefore, providing a new strategies for pancreatic cancer. Based on our findings and other reports, we propose a mechanism by which XN induces apoptosis in pancreatic cancer cells demonstrating possible cross talk between Notch, PI3K-Akt pathway, and the NF-kB pathway reported in other cancer types (Fig. 6 ).
In vivo, XN has been shown to reduce the growth of poorly differentiated prostate tumors without adverse side effects (12) suggesting that XN may be a novel agent for the management of 
